Susquehanna International Group’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-26,255
| Closed | -$119K | – | 12207 |
|
|
2025
Q3 | $119K | Sell |
26,255
-32,956
| -56% | -$97.2K | ﹤0.01% | 11460 |
|
|
2025
Q2 | $127K | Buy |
59,211
+21,877
| +59% | +$61.2K | ﹤0.01% | 11627 |
|
|
2025
Q1 | $163K | Buy |
+37,334
| New | +$168K | ﹤0.01% | 11145 |
|
|
2024
Q1 | – | Sell |
-19,587
| Closed | -$298K | – | 12062 |
|
|
2023
Q4 | $147K | Buy |
19,587
+15,317
| +359% | +$140K | ﹤0.01% | 10992 |
|
|
2023
Q3 | $64.1K | Buy |
4,270
+1,916
| +81% | +$34.4K | ﹤0.01% | 11186 |
|
|
2023
Q2 | $37.4K | Sell |
2,354
-5,967
| -72% | -$62.7K | ﹤0.01% | 11447 |
|
|
2023
Q1 | $59.7K | Buy |
8,321
+7,060
| +560% | +$49.9K | ﹤0.01% | 11614 |
|
|
2022
Q4 | $7.3K | Buy |
+1,261
| New | +$9.56K | ﹤0.01% | 11985 |
|
|
2022
Q3 | – | Sell |
-9,489
| Closed | -$125K | – | 13070 |
|
|
2022
Q2 | $113K | Buy |
+9,489
| New | +$99.4K | ﹤0.01% | 11352 |
|
|
2022
Q1 | – | Sell |
-2,231
| Closed | -$32.6K | – | 12888 |
|
|
2021
Q4 | $39K | Buy |
2,231
+759
| +52% | +$15.2K | ﹤0.01% | 12664 |
|
|
2021
Q3 | $32K | Sell |
1,472
-15,467
| -91% | -$395K | ﹤0.01% | 12472 |
|
|
2021
Q2 | $593K | Buy |
16,939
+14,539
| +606% | +$783K | ﹤0.01% | 9180 |
|
|
2021
Q1 | $237K | Buy |
2,400
+295
| +14% | +$35.4K | ﹤0.01% | 11091 |
|
|
2020
Q4 | $228K | Sell |
2,105
-6,711
| -76% | -$830K | ﹤0.01% | 9818 |
|
|
2020
Q3 | $908K | Buy |
8,816
+3,679
| +72% | +$551K | ﹤0.01% | 6345 |
|
|
2020
Q2 | $1.07M | Sell |
5,137
-5,913
| -54% | -$1.05M | ﹤0.01% | 5761 |
|
|
2020
Q1 | $1.08M | Buy |
11,050
+1,346
| +14% | +$157K | ﹤0.01% | 5230 |
|
|
2019
Q4 | $1.12M | Sell |
9,704
-23,592
| -71% | -$2.08M | ﹤0.01% | 5305 |
|
|
2019
Q3 | $1.81M | Buy |
33,296
+30,008
| +913% | +$3.38M | ﹤0.01% | 4407 |
|
|
2019
Q2 | $391K | Buy |
+3,288
| New | +$272K | ﹤0.01% | 7782 |
|
|
2019
Q1 | – | Sell |
-1,604
| Closed | -$51K | – | 8719 |
|
|
2018
Q4 | $51K | Buy |
+1,604
| New | +$65.2K | ﹤0.01% | 8475 |
|
|
2018
Q2 | – | Sell |
-53,431
| Closed | -$3.21M | – | 9517 |
|
|
2018
Q1 | $3.1M | Buy |
53,431
+39,537
| +285% | +$2.46M | ﹤0.01% | 3207 |
|
|
2017
Q4 | $486K | Buy |
+13,894
| New | +$457K | ﹤0.01% | 6699 |
|
|
2017
Q3 | – | Sell |
-6,471
| Closed | -$162K | – | 8734 |
|
|
2017
Q2 | $162K | Buy |
+6,471
| New | +$177K | ﹤0.01% | 8449 |
|
|
2017
Q1 | – | Sell |
-5,488
| Closed | -$159K | – | 8834 |
|
|
2016
Q4 | $159K | Buy |
+5,488
| New | +$179K | ﹤0.01% | 8812 |
|
|
2016
Q3 | – | Sell |
-2,952
| Closed | -$93K | – | 8334 |
|
|
2016
Q2 | $93K | Buy |
+2,952
| New | +$133K | ﹤0.01% | 8056 |
|
|
2016
Q1 | – | Sell |
-1,072
| Closed | -$59.9K | – | 8933 |
|
|
2015
Q4 | $102K | Sell |
1,072
-6,756
| -86% | -$594K | ﹤0.01% | 8871 |
|
|
2015
Q3 | $645K | Sell |
7,828
-3,692
| -32% | -$472K | ﹤0.01% | 6625 |
|
|
2015
Q2 | $1.87M | Sell |
11,520
-3,328
| -22% | -$1.12M | ﹤0.01% | 4866 |
|
|
2015
Q1 | $6.02M | Buy |
+14,848
| New | +$6.28M | ﹤0.01% | 2482 |
|
Susquehanna International Group's ADVM Position: Q4 2025 in Review
Susquehanna International Group sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 26,255 shares — an estimated $119K sold.
Susquehanna International Group first reported a position in ADVM in Q1 2015 and held it in 30 quarters. The position peaked at $6.02M in Q1 2015. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Susquehanna International Group reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Susquehanna International Group sold 26,255 Adverum Biotechnologies shares in Q4 2025, an estimated $119K.
- Susquehanna International Group first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 30 quarters.
- Susquehanna International Group's Adverum Biotechnologies position peaked at $6.02M in Q1 2015.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.